Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells

Cancer Research

Volumn 62, Issue 21, 2002, Pages 6323-6328

  Sun, Yunjie ^a   Tang, Xi Ming ^a   Half, Elizabeth ^a   Kuo, M Tien ^a   Sinicrope, Frank A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; COMPLEMENTARY DNA; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME C; FLUOROURACIL; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN BCL 2; SULINDAC SULFIDE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME RELEASE; GENE CONTROL; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CASPASES; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; CYTOCHROME C GROUP; DINOPROSTONE; ENZYME ACTIVATION; FLUOROURACIL; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MITOCHONDRIA; NITROBENZENES; NUCLEIC ACID SYNTHESIS INHIBITORS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; SULFONAMIDES; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0036829336     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Greenlee, R., Hill-Harmon, M. B., Murray, T., and Thun, M. J. Cancer statistics, 2001. CA Cancer J. Clin., 51: 15-36, 2001.
2. Williams, C. S., Mann, M., and DuBois, R. N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene, 18: 7908-7915, 1999.
3. Jones, D. A., Carlton, D. P., McIntyre, T. M., Zimmerman, G. A., and Prescott, S. M. Molecular cloning of human prostaglandin endoperoxidase synthase type 2 and demonstration of expression in response to cytokines. J. Biol. Chem., 268: 9049-9054, 1993.
4. Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrebach, S., and Dubois, R. N. Up-regulation of cyclooxygenase2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 107: 1183-1188, 1994.
5. Sinicrope, F. A., Lemoine, M., Xi, L., Lynch, P. M., Cleary, K. R., Shen, Y., and Frazier, M. L. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology, 117: 350-358, 1999.
6. Molina, M. A., Sitja-Arnau, M., Lemoine, M. G., Frazier, M. L., and Smicrope, F. A. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res., 59: 4356-4362, 1999.
7. Wilson, K. T., Fu, S., Ramanujam, K. S., Meltzer, S. J. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett’s esophagus and associated adenocarcinomas. Cancer Res., 58: 2929-2934, 1998.
8. Ristimaki, A., Honkanen, N., Jankala, H., Sipponen, P., and Harkonen, M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res., 57: 1276-1280, 1997.
9. Half, E., Tang, X. M., Gwyn, K., Sahin, A., Wathen, K., and Sinicrope, F. A. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res., 62: 1676-1681, 2002.
10. Hida, T., Yatabe, Y., Achiwa, H., Muramatsu, H., Kozaki, K., Nakamura, S., Ogawa, M., Mitsudomi, T., Sogiura, T., and Takahashi, T. Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res., 58: 3761-3764, 1998.
11. Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., and Taketo, M. M. Suppression of intestinal polyposis in Apc δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.
12. Liu, C. H., Chang, S., Narko, K., Trifan, O. C., Wu, M., Smith, E., Haudenschild, C., Lane, T. F., and Hla, T. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem., 276: 18563-18569, 2001.
13. Thun, M. J., Namboodiri, M. M., and Heath, C. W., Jr. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 325: 1593-1596, 1991.
14. Giovannucci, E., Rimm, E. B., Stampfer, M. J., Colditz, G. A., Ascherio, A., and Willett, W. C. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med., 121: 241-246, 1994.
15. Giovannucci, E., Egan, K. M., Hunter, D. J., Stampfer, M. J., Colditz, G. A., Willett, W. C., and Speizer, F. E. Aspirin and the risk of colorectal cancer in women. N. Eng. J. Med., 333: 609-614, 1995.
16. Smalley, W., Ray, W. A., Daugherty, J., and Griffin, M. R. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: A population-based study. Arch. Intern. Med., 159: 161-166, 1999.
17. Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., and Offerhaus, G. J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Eng. J. Med., 328: 1313-1316, 1993.
18. Steinbach, G., Lynch, P., Phillips, R., Wallace, M., Hawk, E., Gordon, G., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., Su, L., and Levin, B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Eng. J. Med., 342: 1946-1952, 2000.
19. Feldman, M., and McMahon, A. T. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann. Intern. Med., 132: 134-143, 2000.
20. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., Kvien, T. K., and Schnitzer, T. J. VIGOR. Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med., 343: 1520-1528, 2000.
21. Kawamori, T., Rao, C. V., Seibert, K., and Reddy, B. S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res., 58: 409-412, 1998.
22. Jacoby, R. F., Marshall, D. J., Newton, M. A., Novakovic, K., Tutsch, K., Cole, C. E., Lubet, R. A., Kelloff, G. J., Verma, A., Moser, A. R., and Dove, W. F. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res., 56: 710-714, 1996.
23. Boolbol, S. K., Dannenberg, A. J., Chadburn, A., Martucci, C., Gun, X. J., Ramonetti, J. T., Abreu-Goris, M., Newmark, H. L., Lipkin, M. L., DeCosse, J. J., and Bertagnolli, M. M. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res., 56: 2556-2560, 1996.
24. Mahmoud, N. N., Boolbol, S. K., Dannenberg, A. J., Mestre, J. R., Bilinski, R. T., Martucci, C., Newmark, H. L., Chadburn, A., and Bertagnolli, M. M. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis (Lond.), 19: 87-91, 1998.
25. Keller, J. J., Offerhaus, G. J., Polak, M., Goodman, S. N., Zahurak, M. L. Hylind, L. M., Hamilton, S. R., and Giardiello, F. M. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac. Gut. 45: 822-828, 1999.
26. Samaha, H. S., Kelloff, G. J., Stelle, V., Rao, C. V., and Reddy, B. S. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: Apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res., 57: 1301-1305, 1997.
27. Roy, H. K., Karoski, W. J., Ratashak, A., and Smyrk, T. C. Chemoprevention of intestinal tumorigenesis by nabumetone: Induction of apoptosis and Bcl-2 downregulation. Br. J. Cancer, 84: 1412-1416, 2001.
28. Li, H., Schut, H. A., Conran, P., Kramer, P. M., Lubet, R. A., Steele, V. E., Hawk, E. E., Kelloff, G. J., and Pereira, M. A. Prevention by aspirin and its combination with α-difluoromethylomithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis (Lond.), 20: 425-430, 1999.
29. Shiff, S. J., Qiao, L., Tsai, L. L., and Rigas, B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J. Clin. Investig., 96: 491-503, 1995.
30. Piazza, G. A., Rahm, A. L., Krutzsch, M., Sperl, G., Paranka, N. S., Gross, P. H., Brendel, K., Burt, R. W., Alberts, D. S., and Pamukcu, R. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res., 55: 3110-3116, 1995.
31. Elder, D. J., Halton, D. E., Hague, A., and Paraskeva, C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: Independence from COX-2 protein expression. Clin. Cancer Res., 3: 1679-1683, 1997.
32. Hanif, R., Pittas, A., Feng, Y., Koutsos, M. I., Qiao, L., Staiano-Coico, L., Shiff, S. I., and Rigas, B. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol., 52: 237-245, 1996.
33. Piazza, G. A., Alberts, D. S., Hixson, L. J., Paranka, N. S., Li, H., Finn, T., Bogert, C., Guillen, J. M., Brendel, K., Gross, P. H., Sperl, G., Ritchie, Burt, R. W., Ellsworth, L., Ahnen, D. J., and Pamukcu, R. Suiindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res., 57: 2909-2915, 1997.
34. Tsujii, M., and DuBois, R. N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell, 83: 493-501, 1995.
35. Elder, D. J., Halton, D. E., Crew, T. E., and Paraskeva, C. Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398. Int. J. Cancer, 86: 553-560, 2000.
36. Zhang, X., Morham, S. G., Lagenbach, R., and Young, D. A. Malignant transformation and antineoplastic actions of nonsteroidal anti-inflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J. Exp. Med., 190: 451-460, 1999.
37. Reed. J. C., Miyashita, T., Takayama, S., Wang, H. G., Sato, T., Krajewski, S. Aime-Sempe, C., Bodrug, S., Kitada, S., and Hanada, M. BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J. Cell. Biochem., 60: 23-32, 1996.
38. Green, D. R., and Reed, J. C. Mitochondria and apoptosis. Science (Wash. DC). 281: 1309-1312, 1998.
39. Ashkenazi, A., and Dixit, V. M. Apoptosis control by death and decoy receptors. Curr. Opin. Cell. Biol., 11: 225-260, 1999.
40. Martinou, J. C., Desagher, S., and Antonsson, B. Cytochrome c release from mitochondria: All or nothing. Nat. Cell. Biol., 2: E41-E43, 2000.
41. Kluck, R. M., Bossy-Wetzel, E., Green, D. R., and Newmeyer, D. D. The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science (Wash. DC), 275: 1132-1136, 1997.
42. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S. and Wang, X. Cytochrome c and dATP-dependent formation of Apaf-2/Caspase-9 complex initiates an apoptotic protease cascade. Cell, 91: 479-489, 1997.
43. Yang, J., Liu, X., Bhalla, K., Kim, C. N., Ibrado, A. M., Cai, J., Peng, T. I., Jones, D. P., and Wang, X. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. Science (Wash. DC), 275: 1129-1132, 1997.
44. Tsujimoto, Y., and Shimizu, S. Bcl-2 family: Life-or-death switch. FEBS Lett., 466: 6-10, 2000.
45. Murphy, K. M., Ranganathan, V., Farnsworth, M. L., Kavallaris, M., and Lock, R. B. Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells. Cell Death Differ., 7: 102-111, 2000.
46. Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., Goddard, A. D., Godowski, P., and Ashkenazi, A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (Wash. DC), 277: 818-821, 1997.
47. Tatebe, S., Unate, H., Sinicrope, F. A., Sakatani, T., Sugamura, K., Makino, M., Ito, H., Savaraj, N., Kaibara, N., and Kuo, M. T. Expression of heavy subunit of γ-glutamylcysteine synthetase (γ-GCSh) in human colorectal carcinoma. Int. J. Cancer, 97: 21-27, 2002.
48. Maldve, R. E., Kim, Y., Muga, S. J., and Fischer, S. M. Prostaglandin E2 regulation of cyclooxygenase expression in keratinocytes is mediated via cyclic nucleotide-linked prostaglandin receptors. J. Lipid Res., 41: 873-881, 2000.
49. Sheng, H., Shao, J., Kirkland, S. C., Isakson, P., Coffey, R. J., Morrow, J., Beauchamp, R. D., and DuBois, R. N. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Investig., 99: 2254-2259, 1997.
50. Tsujii, M., Kawano, S., and DuBois, R. N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. USA. 94: 3336-3340, 1997.
51. Keller, J. J., Offerhaus, G. J., Drillenburg, P., Caspers, E., Musler, A., Ristamaki, A., and Giardiello, F. M. Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis. Clin. Cancer Res., 7: 4000-4007, 2001.
52. Li, M., Wu, X., and Xu, X-C. Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway. Clin. Cancer Res., 7: 1010-1016, 2001.
53. Zhang, L., Yu, J., Park, B. H., Kinzler, K. W., and Vogelstein, B. Role of BAX in the apoptotic response to anticancer agents. Science (Wash. DC), 290: 989-992, 2000.
54. Huang, Y., He, Q., Hillman, M. J., Rong, R., and Sheikh, M. S. Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells. Can. Res., 61: 6918-6924, 2001.
55. Tang, X., Sun, Y., Half, E., Kuo, M., and Sinicrope, F. A. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res., 62: 4903-4908, 2002.
56. Sheng, H., Shao, J., Morrow, J. D., Beauchamp, R. D., and DuBois, R. N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res., 58: 362-366, 1998.
57. Miyashita, T., Harigai, M., Hanada, M., and Reed, J. C. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res., 54: 3131-3135, 1994.
58. WAF1/CIP1 via C/EBPβ. Nat. Med., 3: 1233-1241, 1997.